Headed to ARVO? You’re invited to dinner CME. Or, join virtually!
May 7, 2024
May 7, 2024
Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with…
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Breast medical oncologist Banu Arun, M.D., discusses breast cancer risk factors and prevention.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.